Predictive Biomarkers as a Guide to Future Therapy Selection in Melanoma

[1]  R. Sullivan,et al.  A single center experience with high-dose (HD) IL-2 treatment for patients with advanced melanoma and pilot investigation of a novel gene expression signature as a predictor of response. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  G. Linette,et al.  Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104) , 2012, Journal of Translational Medicine.

[3]  S. Nelson,et al.  Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.

[4]  V. Sondak,et al.  Melanoma--an unlikely poster child for personalized cancer therapy. , 2010, The New England journal of medicine.

[5]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[6]  T. Gajewski,et al.  Gene Signature in Melanoma Associated With Clinical Activity: A Potential Clue to Unlock Cancer Immunotherapy , 2010, Cancer journal.

[7]  Soonmyung Paik,et al.  Gene-expression-based prognostic assays for breast cancer , 2010, Nature Reviews Clinical Oncology.

[8]  David C. Smith,et al.  Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies. , 2010 .

[9]  K. Flaherty,et al.  Final results of E2603: A double-blind, randomized phase III trial comparing carboplatin (C)/paclitaxel (P) with or without sorafenib (S) in metastatic melanoma. , 2010 .

[10]  A. Tolcher,et al.  A phase I study of RO4929097, a novel gamma secretase inhibitor, in patients with advanced solid tumors. , 2010 .

[11]  Qian Wang,et al.  Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. , 2010, Blood.

[12]  A. Tolcher,et al.  Castration-resistant prostate cancer--hormone therapy redux. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Gutzmer,et al.  Anal Mucosal Melanoma with KIT-Activating Mutation and Response to Imatinib Therapy – Case Report and Review of the Literature , 2009, Dermatology.

[14]  Jimmy Lin,et al.  Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4 , 2009, Nature Genetics.

[15]  R. Vonderheide,et al.  Clinical Use of Anti‐CD25 Antibody Daclizumab to Enhance Immune Responses to Tumor Antigen Vaccination by Targeting Regulatory T cells , 2009, Annals of the New York Academy of Sciences.

[16]  T. Gajewski,et al.  PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. , 2009, Blood.

[17]  F. Marincola,et al.  Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  J. Kirkwood,et al.  Prediction of response to alkylator-based chemotherapy in metastatic melanoma (MM) using gene expression and promoter methylation signatures. , 2009, Journal of Clinical Oncology.

[19]  S. Chasalow,et al.  Association of baseline and on-study tumor biopsy markers with clinical activity in patients (pts) with advanced melanoma treated with ipilimumab. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  G. Schuler,et al.  Association of gene expression profile in metastatic melanoma and survival to a dendritic cell-based vaccine. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Tretiakova,et al.  Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. , 2009, Cancer research.

[22]  V. Sondak,et al.  Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Grou , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  R. Gutzmer,et al.  Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas , 2008, British Journal of Cancer.

[24]  Susan Muller,et al.  KIT Gene Mutations and Copy Number in Melanoma Subtypes , 2008, Clinical Cancer Research.

[25]  M. Ross,et al.  Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib , 2008, Nature Clinical Practice Oncology.

[26]  M. Ross,et al.  Phase II trial of imatinib mesylate in patients with metastatic melanoma , 2008, British Journal of Cancer.

[27]  D. Elder,et al.  A Phase I Trial of the Oral, Multikinase Inhibitor Sorafenib in Combination with Carboplatin and Paclitaxel , 2008, Clinical Cancer Research.

[28]  B. Bastian,et al.  Dose‐dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation , 2008, Pigment cell & melanoma research.

[29]  Hua Yu,et al.  Activated stat-3 in melanoma. , 2008, Cancer control : journal of the Moffitt Cancer Center.

[30]  Jamila Louahed,et al.  Association of gene expression signature and clinical efficacy of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) as adjuvant therapy in resected stage IB/II non-small cell lung cancer (NSCLC) , 2008 .

[31]  D. Schadendorf,et al.  Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy , 2008, Cancer Immunology, Immunotherapy.

[32]  A. D. Van den Abbeele,et al.  Major response to imatinib mesylate in KIT-mutated melanoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  K. McMasters,et al.  Transient T cell depletion causes regression of melanoma metastases , 2008, Journal of Translational Medicine.

[34]  T. Gajewski.  Failure at the Effector Phase: Immune Barriers at the Level of the Melanoma Tumor Microenvironment , 2007, Clinical Cancer Research.

[35]  T. Gajewski,et al.  Chemokines expressed in melanoma metastases associated with T cell infiltration , 2007 .

[36]  D. Germano,et al.  Lapatinib in breast cancer. , 2007, Annals of Oncology.

[37]  R. Salgia,et al.  c-Met Is a Potentially New Therapeutic Target for Treatment of Human Melanoma , 2007, Clinical Cancer Research.

[38]  C. Blank,et al.  Homeostatic Proliferation as an Isolated Variable Reverses CD8+ T Cell Anergy and Promotes Tumor Rejection1 , 2006, The Journal of Immunology.

[39]  M. Ratain,et al.  Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis , 2006, British Journal of Cancer.

[40]  V. Appay,et al.  New Generation Vaccine Induces Effective Melanoma-Specific CD8+ T Cells in the Circulation but Not in the Tumor Site1 , 2006, The Journal of Immunology.

[41]  D. Pinkel,et al.  PI3-kinase subunits are infrequent somatic targets in melanoma. , 2006, The Journal of investigative dermatology.

[42]  Susan O'Brien,et al.  Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. , 2006, The New England journal of medicine.

[43]  M. Atkins,et al.  Multicenter Phase II trial of high‐dose imatinib mesylate in metastatic melanoma , 2006, Cancer.

[44]  A. Bardia,et al.  Hand-foot syndrome after dose-dense adjuvant chemotherapy for breast cancer: a case series. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  T. Gajewski,et al.  Tumor progression despite massive influx of activated CD8+ T cells in a patient with malignant melanoma ascites , 2006, Cancer Immunology, Immunotherapy.

[46]  D. Massi,et al.  Evidence for differential expression of Notch receptors and their ligands in melanocytic nevi and cutaneous malignant melanoma , 2006, Modern Pathology.

[47]  E. Gilboa,et al.  Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. , 2005, The Journal of clinical investigation.

[48]  J. Fridlyand,et al.  Distinct sets of genetic alterations in melanoma. , 2005, The New England journal of medicine.

[49]  S. Steinberg,et al.  Tumor Progression Can Occur despite the Induction of Very High Levels of Self/Tumor Antigen-Specific CD8+ T Cells in Patients with Melanoma , 2005, The Journal of Immunology.

[50]  J. Sosman,et al.  Phase II Trial of the O6-Alkylguanine DNA Alkyltransferase Inhibitor O6-Benzylguanine and 1,3-Bis(2-Chloroethyl)-1-Nitrosourea in Advanced Melanoma , 2005, Clinical Cancer Research.

[51]  G. Prendergast,et al.  Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors , 2005, Expert opinion on therapeutic targets.

[52]  Hua Yu,et al.  Stat3 Activity in Melanoma Cells Affects Migration of Immune Effector Cells and Nitric Oxide-Mediated Antitumor Effects1 , 2005, The Journal of Immunology.

[53]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[54]  S. Rosenberg,et al.  Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[55]  Ping Chen,et al.  Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor , 2004, Science.

[56]  A. Mackensen,et al.  Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. , 2004, Cancer research.

[57]  Tasuku Honjo,et al.  PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells , 2004, Cancer Research.

[58]  A. D. Van den Abbeele,et al.  Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  C. Uyttenhove,et al.  Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase , 2003, Nature Medicine.

[60]  N. Cascinelli,et al.  Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. , 2003, Cancer research.

[61]  Lieping Chen,et al.  B7-H1 pathway and its role in the evasion of tumor immunity , 2003, Journal of Molecular Medicine.

[62]  R. Schwartz.  T cell anergy. , 2003, Annual review of immunology.

[63]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[64]  T. Schumacher,et al.  Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses , 2001, The Journal of experimental medicine.

[65]  P. Coulie,et al.  A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3 , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[66]  C. Eng,et al.  Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. , 2000, The American journal of pathology.

[67]  M. Peacocke,et al.  Identification of PTEN mutations in metastatic melanoma specimens , 2000, Journal of medical genetics.

[68]  D. Munn,et al.  Prevention of allogeneic fetal rejection by tryptophan catabolism. , 1998, Science.

[69]  N. Vogelzang,et al.  Effective chemotherapy for melanoma after treatment with interleukin‐2 , 1992, Cancer.

[70]  L. Larue,et al.  The WNT/Beta-catenin pathway in melanoma. , 2006, Frontiers in bioscience : a journal and virtual library.

[71]  T. Nomura,et al.  Naturally arising CD25+CD4+ regulatory T cells in tumor immunity. , 2005, Current topics in microbiology and immunology.